Business Insider

Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

PARIS and TARRYTOWN, N.Y., March 10, 2018 /PRNewswire/ -- Sanofi (EURONEXT: SAN) (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its primary ...
Healio

FDA approves expanded indication for alirocumab as add-on therapy for homozygous FH

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded indication for alirocumab injection for adult patients with homozygous ...
Seeking Alpha

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...
FiercePharma

Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access

TARRYTOWN, N.Y. and BRIDGEWATER, N.J, Dec. 11, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that UnitedHealth Group will provide preferred access to Praluent ...
News Medical

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the ...
Healio

Alirocumab approval now includes some pediatric patients with lipid disorder

Please provide your email address to receive an email when new articles are posted on . The FDA extended its approval of alirocumab to treat a genetic lipid disorder in patients as young as 8 years.
Medscape

FDA Okays New Indication for Alirocumab in Homozygous FH

The US Food and Drug Administration has approved alirocumab (Praluent, Regeneron Pharmaceuticals) injection as add-on therapy for adults with homozygous familial hypercholesterolemia, the agency ...
FiercePharma

Sanofi and Regeneron Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

- Primary results from ongoing 52 week ODYSSEY JAPAN trial presented at the Japanese Atherosclerosis Society (JAS) Annual Scientific Meeting - - Ninety-nine percent of patients treated with Praluent ...
CNN

Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017

TARRYTOWN, N.Y. and BRIDGEWATER, N.J., Aug. 25, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new analyses from Praluent ® (alirocumab) Injection ...
Business Insider

Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate

TARRYTOWN, N.Y. and PARIS, March 10, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing ...
TCTMD

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

TARRYTOWN, N.Y. and PARIS, Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent ® (alirocumab) Injection met its ...